Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trialsopen access
- Authors
- Combe, Bernard; Allanore, Yannick; Alten, Rieke; Caporali, Roberto; Durez, Patrick; Iannone, Florenzo; Nurmohamed, Michael T.; Toumi, Mondher; Lee, Sang Joon; Kwon, Taek Sang; Noh, Jiwon; Park, Gahee; Yoo, Dae Hyun
- Issue Date
- Apr-2021
- Publisher
- BMC
- Keywords
- CT-P13; Disease activity; Indirect treatment comparison; Individual patient data; Infliximab; Intravenous; Network meta-regression; Rheumatoid arthritis; Subcutaneous; Tumour necrosis factor inhibitor
- Citation
- ARTHRITIS RESEARCH & THERAPY, v.23, no.1, pp.1 - 11
- Indexed
- SCIE
SCOPUS
- Journal Title
- ARTHRITIS RESEARCH & THERAPY
- Volume
- 23
- Number
- 1
- Start Page
- 1
- End Page
- 11
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/1240
- DOI
- 10.1186/s13075-021-02487-x
- ISSN
- 1478-6354
- Abstract
- BackgroundA subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It may offer improved efficacy versus intravenous (IV) infliximab formulations.MethodsA network meta-regression was conducted using individual patient data from two randomised trials in patients with RA, which compared CT-P13 SC with CT-P13 IV, and CT-P13 IV with reference infliximab IV. In this analysis, CT-P13 SC was compared with CT-P13 IV, reference infliximab IV and pooled data for both reference infliximab IV and CT-P13 IV. Outcomes included changes from baseline in 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI), and rates of remission, low disease activity or clinically meaningful improvement in functional disability per Health Assessment Questionnaire-Disability Index (HAQ-DI).ResultsThe two studies enrolled 949 patients with RA; pooled data for 840 and 751 patients were evaluable at weeks 30 and 54, respectively. For the CT-P13 SC versus pooled IV treatment arm comparison, differences in changes from baseline in DAS28-CRP (-0.578; 95% confidence interval [CI] -0.831, -0.325; p<0.0001), CDAI (-3.502; 95% CI -5.715, -1.289; p=0.002) and SDAI (-4.031; 95% CI -6.385, -1.677; p=0.0008) scores at 30weeks were statistically significant in favour of CT-P13 SC. From weeks 30 to 54, the magnitude of the differences increased and remained statistically significant in favour of CT-P13 SC. Similar results were observed for the comparison of CT-P13 SC with CT-P13 IV and with reference infliximab IV. Statistically significant differences at week 30 favoured CT-P13 SC over the pooled IV treatment arms for the proportions of patients achieving EULAR-CRP good response, American College of Rheumatology (ACR) 50 and ACR70 responses, DAS28-CRP-defined remission, low disease activity (DAS28-CRP, CDAI and SDAI criteria) and clinically meaningful HAQ-DI improvement.ConclusionsCT-P13 SC was associated with greater improvements in DAS28-CRP, CDAI and SDAI scores and higher rates of clinical response, low disease activity and clinically meaningful improvement in functional disability, compared with CT-P13 IV and reference infliximab IV.Trial registrationEudraCT, 2016-002125-11, registered 1 July 2016; EudraCT 2010-018646-31, registered 23 June 2010.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/1240)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.